News + Filings IR Vault
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results CC transcript Inv. presentation Appointed director Director departure Credit agrmnt [a] Asset disposition Acq. announced Appointed CFO Consulting agrmnt Auditor change Notes underwriting agrmnt Director comp. Employment agrmnt Dividend declared Appointed COO Filed Chapter 11 Monthly dividend Preliminary results Accel. buyback Cert. of designation Acq. completed Monthly oper. report Merger agrmnt [a] Quarterly results presentation Class action filed CFO resigned Departure of a VP SSS news release Asset acq. complete Letter to company Buyback announced Bonus plan approved Upcoming conference date Notes have priced Coll. bargaining agrmnt 10-Q late filing RE purchase Amended bylaws New credit facility
|
All Companies
|
Create: Portfolio | Alert |
All | News | Filings
Date Filed | Symbol | Type | Description |
10/05/2023 |
******
|
8-K
| Entered into consulting agreement |
10/05/2023 |
EXDI
|
8-K
| Entered into consulting agreement
Docs:
|
"FORM OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES N-7 CONVERTIBLE PREFERRED STOCK The undersigned, Chief Executive Officer of Panacea Life Sciences Holdings, Inc., a Nevada corporation , DOES HEREBY CERTIFY that the following resolutions were duly adopted by the Board of Directors of the Corporation by unanimous written consent on June 30, 2023; WHEREAS, the Board of Directors is authorized within the limitations and restrictions stated in the Articles of Incorporation of the Corporation, as amended, to provide by resolution or resolutions for the issuance of 50,000,000 shares of Preferred Stock, par value $0.0001 per share, of the Corporation, in such series and with such designations, preferences and relative, participating, optional or other special rig...",
"FORM OF ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT is entered into as of June 30, 2023 , by and among Panacea Life Sciences Holdings, Inc., a Nevada corporation, or its assigns , Lizard Juice, LLC, a Delaware limited liability company , Gary Wilder, an individual resident of Florida , New Age Distribution, LLC, a Florida limited liability company , and N7 Enterprises, Inc., a Florida corporation and the parent company of Lizard Juice and New Age Distribution , and collectively together with Lizard Juice, Wilder and New Age Distribution, its and their respective subsidiaries, affiliates and assigns, the “ Seller ” or “ Sellers ”), and each of the Holders . Sellers and PLSH, as applicable, and Holders, as applicable, are sometimes referred to individually as a “ Party ” and colle...",
"FORM OF BILL OF SALE THIS BILL OF SALE is entered into on September 30, 2023, y and among Panacea Life Sciences Holdings, Inc., a Nevada corporation, or its assigns , Lizard Juice, LLC, a Delaware limited liability company , Gary Wilder, an individual resident of Florida , New Age Distribution, LLC, a Florida limited liability company , and N7 Enterprises, Inc., a Florida corporation and the parent company of Lizard Juice and New Age Distribution , for the benefit of Buyer. Recitals A. Sellers and Buyer, among others, entered into that certain Asset Purchase Agreement dated June 30, 2023 , whereby Buyer agreed to purchase the Assets from Sellers; and B. Capitalized terms not defined herein have the respective meanings ascribed to them in the APA. NOW THEREFORE, Sellers certifies as follows...",
"FORM OF PLEDGE AND SECURITY AGREEMENT This PLEDGE AND SECURITY AGREEMENT , made as of June 30, 2023, by and among Gary Wilder, a Florida resident and Panacea Life Sciences Holdings, Inc., a Nevada corporation . RECITALS WHEREAS, the Parties entered into that certain asset purchase agreement dated June 30, 2023 , pursuant to which, among other things, Pledgor will acquire 31,000 shares of Series N7 Convertible Preferred Stock of Panacea Life Sciences Holdings, Inc. , convertible into 3,100,000 common shares of the Company’ s common stock, par value $0.0001 ; and WHEREAS, Pledgor has agreed to pledge the Pledged Shares for the period beginning at the Signing Date of the Asset Purchase Agreement and ending twenty-four months thereafter to secure the indemnification obligations of the Sellers ...",
"CONSULTING AGREEMENT",
"Panacea Life Sciences Holdings, Inc. 16194 West 45th Drive Golden, CO 80403 September 30, 2023 VIA EMAIL Gary Wilder 8565 Somerset Dr., Suite A Largo, FL 33770",
"FORM OF LEAK OUT AGREEMENT This LEAK-OUT AGREEMENT is made as of September 30, 2023 by and between Panacea Life Sciences Holdings, Inc. a Nevada corporation, , and the undersigned of the Company. WHEREAS, to ensure the development of an orderly trading market in the Company’ s common stock , the Company and the Stockholder intend to enter into this Agreement to provide for the circumstances under which the Stockholder may sell or otherwise dispose of shares of the Company’ s securities; and WHEREAS, pursuant to that certain Asset Purchase Agreement dated as of June 30, 2023 , Stockholder is the holder of shares of Series N7 Preferred Stock of the Company . NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement and the Asset Purchase Agreement, and for other go..." |
|
10/04/2023 |
IMNM
|
8-K
| Entered into consulting agreement
Docs:
|
"CERTIFICATE OF MERGER MERGING IBIZA MERGER SUB, INC., A DELAWARE CORPORATION WITH AND INTO MORPHIMMUNE INC., A DELAWARE CORPORATION Pursuant to Title 8, Section 251 of the General Corporation Law of the State of Delaware Pursuant to Title 8, Section 251 of the Delaware General Corporation Law , the undersigned corporation executed the following Certificate of Merger: FIRST: The name of the surviving corporation is Morphimmune Inc., a Delaware corporation , and the name of the corporation being merged into this surviving corporation is Ibiza Merger Sub, Inc., a Delaware corporation . SECOND: An Agreement and Plan of Merger and Reorganization, dated June 29, 2023 , by and among Immunome, Inc., a Delaware corporation, Merger Sub and the Company, setting forth the terms and conditions of the m...",
"CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNOME, INC. It is hereby certified that: FIRST : The name of the corporation is Immunome, Inc. . SECOND : The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended by adding new Article IX as follows: IX.",
"CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNOME, INC.",
"Immunome and Morphimmune Announce Successful Completion of Merger with" |
|
08/14/2023 |
NVNT
|
8-K
| Certificate of designation filed, Entered into consulting agreement
Docs:
|
"Share Exchange Agreement, by and among the Company, Dror Ortho-Design Ltd., and certain shareholders of Dror Ortho-Design Ltd",
"Amendment to the Share Exchange Agreement, by and among the Company, Dror Ortho-Design Ltd., and certain shareholders of Dror Ortho-Design Ltd",
"Amended and Restated Certificate of Incorporation of Dror Ortho-Design, Inc",
"Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock",
"Form of Class A Common Stock Purchase Warrant",
"EMPLOYMENT AGREEMENT",
"EMPLOYMENT AGREEMENT",
"INDEMNIFICATION AGREEMENT",
"Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)",
"INDEMNIFICATION AGREEMENT" |
|
07/07/2023 |
CANN
|
8-K
| Entered into consulting agreement
Docs:
|
"SETTLEMENT AGREEMENT",
"TERMINATION OF EMPLOYMENT AGREEMENT AND MUTUAL GENERAL RELEASE THIS TERMINATION OF EMPLOYMENT AGREEMENT AND MUTUAL GENERAL RELEASE is entered into as of July 1, 2023 , by and between Allyson Feiler Downing, an individual , and TREES Corporation, a Colorado corporation . WHEREAS, Employee has served as the Chief Marketing Officer of the Company pursuant to an Employment Agreement dated December 12, 2022 by and between the Company and Employee ; and WHEREAS, the parties wish to terminate the Employment Agreement and provide the mutual releases as set forth herein. NOW, THEREFORE, in consideration of the mutual promises, agreements and covenants contained herein, and for other valuable consideration, receipt of which is hereby acknowledged, the parties, intending to be legally bound, agree as...",
"TERMINATION OF EMPLOYMENT AGREEMENT AND MUTUAL GENERAL RELEASE THIS TERMINATION OF EMPLOYMENT AGREEMENT AND MUTUAL GENERAL RELEASE is entered into as of July 1, 2023 , by and between LOREE SCHWARTZ, an individual , and TREES Corporation, a Colorado corporation . WHEREAS, Employee has served as the Chief Marketing Officer of the Company pursuant to an Employment Agreement dated December 12, 2022 by and between the Company and Employee ; and WHEREAS, the parties wish to terminate the Employment Agreement and provide the mutual releases as set forth herein. NOW, THEREFORE, in consideration of the mutual promises, agreements and covenants contained herein, and for other valuable consideration, receipt of which is hereby acknowledged, the parties, intending to be legally bound, agree as follows...",
"215 Union Boulevard, Suite 415",
"CONSULTING AGREEMENT",
"Transition Services Agreement" |
|
07/05/2023 |
AEL
|
8-K
| Entered into consulting agreement |
06/01/2023 |
******
|
8-K
| Acquisition/merger/asset purchase announced, Entered into consulting agreement |
05/18/2023 |
ALIM
|
8-K
| Entered into consulting agreement, Appointed a new director
Docs:
|
"Exhibit 2.1 PRODUCT RIGHTS AGREEMENT between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc. May 17, 2023",
"RESOLVED, that a new Section 7 is hereby added to the Certificate of Designation as follows: consummate a Liquidation Transaction. SECOND: The foregoing amendments were duly adopted in accordance with the provisions of Section 103 and 242 of the DGCL. IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer on May 16, 2023. ALIMERA SCIENCES, INC.",
"In Witness Whereof, the Parties intending to be bound have caused this Commercial Supply Agreement to be executed by their duly authorized representatives as of the Effective Date. EYEPOINT PHARMACEUTICALS, INC. By: /s/ Nancy Lurker Name: Nancy Lurker Title: Chief Executive Officer ALIMERA SCIENCES, INC. By: /s/ Richard S. Eiswirth, Jr. Name: Richard S. Eiswirth, Jr. Title: Chief Executive Officer [Signature Page to Commercial Supply Agreement] EXHIBIT A PRODUCT SPECIFICATIONS [***] EXHIBIT B INITIAL ROLLING FORECAST [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]",
"Exhibit 10.2",
"Alimera Acquires U.S. Commercial Rights to YUTIQ®" |
|
03/27/2023 |
AMIH
|
8-K
| Entered into consulting agreement |
03/21/2023 |
ADTX
|
8-K
| Entered into consulting agreement |
03/20/2023 |
******
|
8-K
| Quarterly results |
03/01/2023 |
IMRA
|
8-K
| Acquisition/merger/asset purchase announced, Entered into consulting agreement
Docs:
|
"Certificate of Amendment to the Company’s Restated Certificate of Incorporation",
"Certificate of Amendment to the Company’s Restated Certificate of Incorporation",
"Contingent Value Rights Agreement between the Company and Rights Agent",
"November 10, 2022",
"February 14, 2020",
"Rahul Ballal Separation Agreement",
"March 15, 2022",
"ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter",
"ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter",
"Contingent Value Rights Agreement between the Company and Rights Agent" |
|
02/06/2023 |
MCHX
|
8-K
| Entered into consulting agreement |
12/21/2022 |
OCX
|
8-K
| Quarterly results |
12/14/2022 |
TCFC
|
8-K
| Quarterly results |
12/14/2022 |
SHBI
|
8-K
| Quarterly results |
11/23/2022 |
******
|
8-K
| Entered into consulting agreement |
11/18/2022 |
FCBC
|
8-K
| Quarterly results |
11/15/2022 |
QSP.UN
|
8-K
| Entered into consulting agreement |
11/15/2022 |
QSR
|
8-K
| Entered into consulting agreement |
11/09/2022 |
IMUN
|
8-K
| Quarterly results |
11/08/2022 |
SBTX
|
8-K
| Entered into consulting agreement
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC.,",
"Certificate of Amendment to Amended and Restated Certificate of Incorporation of Silverback Therapeutics, Inc",
"Certificate of Merger",
"Warrant to purchase stock issued to Silicon Valley Bank, as amended on December 7, 2020",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Confidential LICENSE AGREEMENT between ARS PHARMACEUTICALS, INC. and AEGIS THERAPEUTICS, LLC",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Confidential COLLABORATION AND DISTRIBUTION AGREEMENT",
"Cover Page Interactive Data File (embedded within the Inline XBRL document",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL.",
"9. Section 409A. It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1, 1.409A-1 and 1.409A-1, and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A ), Executive's right to receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. ..." |
|
10/14/2022 |
******
|
8-K
| Entered into consulting agreement |
09/21/2022 |
ACY
|
8-K
| Entered into consulting agreement
Docs:
|
"TERMINATION AGREEMENT THIS TERMINATION AGREEMENT, dated as of September 16, 2022, is by and between Mega Matrix Corp. a Delaware Corporation , and Florence Ng . WHEREAS On October 1, 2021, the Company and the Employee entered into an employment agreement , pursuant to which the Employee was appointed as an executive director and general counsel. On October 1, 2021, Yucheng Hu has issued an undertaking, pursuant to which, as the CEO of the Company, undertook to procure the Company to pay for rent expense of Florence Ng, for a period of three years from October 1, 2021 . On November 1, 2021, the Company and the Employee entered into an amendment to the Employment Agreement , pursuant to which the Employee amended her title and responsibility from “General Counsel” to “VP of Operations and Bu...",
"CONSULTING AGREEMENT",
"CONSULTING AGREEMENT" |
|
08/23/2022 |
FRTG
|
8-K
| Quarterly results |
08/22/2022 |
CLSH
|
8-K
| Quarterly results |
08/18/2022 |
ATIF
|
8-K
| Quarterly results |
06/06/2022 |
LUB
|
8-K
| Quarterly results |
06/01/2022 |
PAYM
|
8-K
| Quarterly results |
04/28/2022 |
******
|
8-K
| Entered into consulting agreement |
03/22/2022 |
CYIM
|
8-K
| Entered into consulting agreement |
03/14/2022 |
HEP
|
8-K
| Entered into consulting agreement
Docs:
|
"Eighth Amended and Restated Master Throughput Agreement entered into and effective as of March 14, 2022, by and among HollyFrontier Refining & Marketing LLC, Sinclair Oil LLC and Holly Energy Partners – Operating, L.P",
"Twenty-Second Amended and Restated Omnibus Agreement entered into and effective as of March 14, 2022, by and among HF Sinclair Corporation, Holly Energy Partners, L.P., and certain of their respective subsidiaries",
"Seventh Amended and Restated Master Lease Agreement entered into and effective as of March 14, 2022, by and among certain subsidiaries of HF Sinclair Corporation and Holly Energy Partners, L.P",
"HollyFrontier and Holly Energy Partners Announce Completion of Transactions with The Sinclair Companies and Establishment of New Parent Company, HF Sinclair Corporation" |
|
03/03/2022 |
HEB
|
8-K
| Quarterly results |
02/28/2022 |
SVMK
|
8-K
| Quarterly results |
|
|
|